See more : Krka, d. d. (KRK.WA) Income Statement Analysis – Financial Results
Complete financial analysis of BriaCell Therapeutics Corp. (BCTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BriaCell Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Straumann Holding AG (STMN.SW) Income Statement Analysis – Financial Results
- S.P. Korolev Rocket and Space Public Corporation Energia Open Joint Stock Company (RKKE.ME) Income Statement Analysis – Financial Results
- Duke Offshore Limited (DUKEOFS.BO) Income Statement Analysis – Financial Results
- Real Estate Investors plc (RLE.L) Income Statement Analysis – Financial Results
- Hang Lung Group Limited (HNLGF) Income Statement Analysis – Financial Results
BriaCell Therapeutics Corp. (BCTX)
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 82.58K | 15.53K | 15.14K | 15.57K | 13.99K | 14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -82.58K | -15.53K | -15.14K | -15.57K | -13.99K | -14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.75M | 15.34M | 8.02M | 1.32M | 2.22M | 3.74M | 2.39M | 1.71M | 723.43K | 105.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -178.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.97M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 114.12K | 129.06K | 8.58K |
| Other Expenses | 0.00 | 0.00 | -15.29M | -1.33M | -2.24M | -3.75M | -312.92K | 290.00 | 1.79K | 565.00 | 1.21K | 404.00 | -4.23K | 2.40K | 1.33K | 2.33K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 32.73M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Cost & Expenses | 32.81M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Interest Income | 0.00 | 891.21K | 136.73K | 3.15K | 39.48 | 9.13K | 12.27K | 5.16K | 3.63K | 7.09K | 12.00K | 16.90K | 38.01K | 13.36K | 2.90K | 2.73K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 979.00 | 46.10K | 27.00K | 23.82K | 15.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 82.58K | 15.27K | 15.27K | 15.26K | 15.26K | 14.25K | 12.97K | 232.68 | 907.21 | 434.31 | 1.11K | 392.08 | 1.72K | 2.51K | 1.29K | 154.20 | 12.72K | 5.10K | -1.13K |
| EBITDA | -4.77M | -30.67M | -15.13M | -8.69M | -3.97M | -6.67M | -4.96M | -3.22M | -2.18M | -1.80M | -2.61K | -462.53K | -68.23K | -1.01M | 255.79K | -233.72K | -114.12K | -129.06K | -8.58K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.81M | -23.27M | -15.29M | 3.69M | 1.38M | 946.42K | -3.82M | -2.58M | -1.67M | -1.44M | -437.27K | -424.26K | -1.20M | -1.05M | -324.57K | -233.87K | -114.12K | -129.06K | -8.58K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 28.02M | 2.97M | 3.74M | -6.84M | -85.10K | 0.00 | -1.59M | 634.11K | 481.60K | -1.24M | -7.71M | 55.56K | 202.71K | -37.17K | -595.34K | 2.51K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -4.79M | -20.30M | -11.55M | 3.69M | 1.38M | 946.42K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.09M | -919.91K | -231.36K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 62.85K | -152.62K | 30.73K | 6.58M | -72.25K | 343.74K | 1.59M | 638.59K | 547.97K | 2.05M | 8.45M | -44.35K | -200.92K | -24.03K | 601.48K | 12.46K | -12.72K | -5.10K | 1.13K |
| Net Income | -4.79M | -20.30M | -11.58M | -2.89M | 1.38M | 602.68K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.08M | -900.74K | -228.81K | -98.93K | -116.41K | -8.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.61 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EPS Diluted | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.32 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| Weighted Avg Shares Out | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.81K | 339.71K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
| Weighted Avg Shares Out (Dil) | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.82K | 352.98K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a poster presentation at...
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report significantly higher...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
PHILADELPHIA and VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces positive clinical efficacy data...
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
PHILADELPHIA and VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces positive clinical data of...
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has closed its...
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has entered into...
BriaCell Announces Oral and Poster Presentations at ASCO 2024
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an...
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report...
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
PHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received...
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that...
Source: https://incomestatements.info
Category: Stock Reports